908 Devices Q3 2026 earnings

MASS · 2026-11-10 07:05 BMO ET · 8-K on SEC · 10-Q on SEC

Revenue grew 35% year-over-year to $19.0 million, with adjusted gross margin stable at 58% and operating expenses declining significantly due to a noncash reduction in contingent consideration.

Headline numbers

MetricActualYoYQoQ8-K location
Revenue$19.0M+35%+18%Ex. 99.1, income statement
EPS (GAAP)-$0.11+0.30+0.21Ex. 99.1, income statement
EPS (adjusted)-$0.11+0.30+0.21Ex. 99.1, income statement
Net income-$4.6M+$10.3M+$7.3MEx. 99.1, income statement
Adj. EBITDA-$1.7M+$0.1M+$0.2MEx. 99.1, income statement
Adj. EBITDA margin9.0%+0.6 pp+1.1 ppEx. 99.1, income statement

Revenue breakdown

SegmentActualYoYShare of revenueNote
Product revenue$15.8M+45%83%FTIR devices
Service and contract revenue$3.2M+1%17%—

Margins and costs

  • Gross margin 53% (prior 53%, change 0.0 pp)
  • Operating expenses $15.5M (+34% YoY)
  • One-offs in the quarter Noncash reduction in contingent consideration of $11.0M; SG&A increase of $2.8M
  • Effective tax rate 1% (prior-year -0.2%, year-to-date 0.4%)
  • Non-GAAP bridge Adds back intangible amortization ($0.8M), stock-based compensation ($0.1M), restructuring ($0.0M), and acquisition and integration costs (none).

KPIs

MetricActualPrior quarterPrior yearChange
Installed base4,409 devices4,101 devices3,502 devices+26% YoY, +8% QoQ
Device shipments308 devices198 devicesN/A+55% QoQ
Recurring revenue27% of total revenue31% of total revenue26% of total revenue-4 pp QoQ, +1 pp YoY

Guidance

MetricGuidePrior guideChange
Full year 2026 revenue$68.5M to $70.0M$68.0M to $70.0M+$0.5M low end

What drove it

  • Revenue story Revenue increased 35% year-over-year to $19.0 million, driven by an increase in product revenue for FTIR devices and the addition of NIRLab revenue.
  • EPS story The EPS move came from a reduction in net loss driven by a significant decrease in operating expenses, primarily due to a noncash reduction in contingent consideration.
  • One-off check Noncash reduction in expense related to the change in fair value of contingent consideration of $11.0M.

The good

  • Revenue grew 35% year-over-year to $19.0 million
  • Adjusted gross margin stable at 58%
  • Operating expenses decreased $8.2 million YoY
  • Device shipments reached a new company record of 308 units

The bad

  • Net loss from continuing operations of $4.6 million
  • Adjusted EBITDA loss of $1.7 million
  • Recurring revenue declined to 27% from 31% in the prior quarter

The ugly

  • none

Open questions

  • The release does not provide a reconciliation of the updated guidance for adjusted gross margin and adjusted EBITDA to GAAP measures.
  • The release does not disclose the specific revenue contribution of the NIRLab acquisition.
Full release

908 Devices (MASS) earnings release, November 10, 2026

908 Devices Inc. (MASS) · Form 8-K, Item 2.02 · Filed · SEC filing

​

​

908 Devices Reports Third Quarter 2026 Financial Results and Achieves Record Revenue

Revenue increased 35% compared to prior year

Raises low end of 2026 revenue outlook

​

​

BURLINGTON, Mass. – November 10, 2026 – 908 Devices Inc. (Nasdaq: MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety, and defense tech applications, today reported financial results for the quarter ended September 30, 2026.

​

"We had a strong third quarter, driven by our FTIR portfolio, with revenue growing 35% year-over-year to $19 million and device shipments reaching a new company record,” said Kevin J. Knopp, CEO and Co-founder. "Our proven platforms are winning orders across the globe as customers accelerate efforts to modernize their detection capabilities and stay ahead of an evolving threat landscape. NIRLab is also gaining traction, both in unit volumes and pipeline, as we build a growing base of connected, recurring revenue. With continued operational discipline and healthy customer funding supporting demand, we are well positioned as we head toward the end of the year.”

​

Recent Highlights

​

Third Quarter 2026 Financial Results

​

Revenue was $19.0 million for the three months ended September 30, 2026, a 35% increase over the prior year period, driven by an increase in product revenue for FTIR devices and the addition of NIRLab revenue. The installed base grew 26% year-over-year to 4,409 devices, with 308 devices placed during the third quarter, a new company record. Recurring revenue represented 27% of total revenues in the quarter.

​

Gross profit was $10.0 million for the third quarter of 2026, compared to $7.4 million for the corresponding period in the prior year. GAAP gross margin was 53% as compared to 53% for the corresponding prior year period. Adjusted gross profit was $10.9 million for the third quarter of 2026, compared to $8.1 million for the corresponding period in the prior year. Adjusted gross margin was 58%, as compared to 58% for the corresponding prior year period.

​

Operating expenses were $15.5 million for the third quarter of 2026, compared to $23.7 million for the corresponding prior year period. The $8.2 million decrease was primarily driven by an $11.0 million noncash reduction in expense related to the change in fair value of contingent consideration, partially offset by a $2.8 million increase in selling, general and administrative expenses.

​

Net loss from continuing operations was $4.6 million for the third quarter of 2026, compared to a net loss from continuing operations of $14.9 million for the corresponding prior year period. Adjusted EBITDA was a loss of $1.7 million for the third quarter of 2026, compared to a loss of $1.8 million for the corresponding period in the prior year.

​

Net loss attributable to common stockholders was $4.6 million for the third quarter of 2026, compared to $15.0 million for the corresponding prior year period.

​

Cash, cash equivalents and marketable securities were $99.1 million as of September 30, 2026, with no debt outstanding.

​

2026 Guidance

​

908 Devices updates its full year revenue guidance range to $68.5 million to $70.0 million (from $68.0 million to $70.0 million previously), raising the low end of the range and representing 22% to 25% growth compared to 2025 revenue.

​

Webcast Information

​

908 Devices will host a conference call to discuss the third quarter 2026 financial results before market open on Tuesday, November 10, 2026 at 8:30 am Eastern Time. A webcast of the conference call can be accessed in the Investor Relations section of 908devices.com. The webcast will be archived and available for replay for at least 90 days after the event.

​

About 908 Devices

​

908 Devices is revolutionizing chemical analysis with its simple handheld devices, addressing life-altering applications. The Company’s devices are used at the point-of-need to interrogate unknown and invisible materials and provide quick, actionable answers in vital health, safety and defense tech applications, addressing the fentanyl and illicit drug crisis, toxic carcinogen exposure, and global security threats. The Company designs and manufactures innovative products that bring together the power of complementary analytical technologies, software automation, and machine learning. For more information, visit www.908devices.com.

​

Non-GAAP Measures of Financial Performance

​

To supplement the Company’s financial statements, which are presented on the basis of U.S. generally accepted accounting principles (GAAP), the following non-GAAP measures of financial performance are included in this release and presented with detailed reconciliations to comparable GAAP financial results in the tables below:

​

​

The Company has not reconciled its guidance for adjusted gross margin and adjusted EBITDA to GAAP gross margin and GAAP net loss from continuing operations, respectively, in reliance on the exception provided by Item 10(e)(1)(i)(B) of Regulation S-K, because certain reconciling items that affect these measures, including changes in the fair value of contingent consideration related to the NIRLAB acquisition, acquisition and integration related costs, and income tax effects, have not occurred, are outside the Company’s control, or cannot be reasonably predicted. Accordingly, reconciliations to the most directly comparable GAAP measures are not available without unreasonable effort. These unavailable items could significantly affect the Company’s GAAP results.

​... (truncated)erations, and as such, excluding these costs allows management to understand and evaluate core operating performance and trends. However, as there are no standardized methods of calculating these non-GAAP financial measures, the Company’s methods may differ from those used by other companies in its industry, and accordingly, the use of these measures may not be directly comparable to similar measures used by others, thus limiting their usefulness for purposes of comparison. Furthermore, these non-GAAP measures have certain limitations since they do not include the impact of certain expenses and cash flows that are reflected in the Company’s GAAP financial results. Accordingly, when analyzing the Company’s operating performance and guidance, investors should not consider non-GAAP measures in isolation or as a substitute for, or superior to, comparable financial measures prepared in accordance with GAAP. Rather, the Company believes that these non-GAAP financial measures, when viewed in addition to and not in lieu of reported GAAP financial results, provide investors with additional meaningful information to assess financial performance and trends, enable comparison of financial results between periods, and allow for greater transparency with respect to key metrics utilized internally in analyzing and operating the Company’s business.

​

​

Forward Looking Statements

​

Financial statements

Income Statement

Three Months Ended September 30, — (unaudited)

Three Months Ended September 30, – 2026Three Months Ended September 30, – 2025Nine Months Ended September 30, – 2026Nine Months Ended September 30, – 2025
Revenue:
Product revenue15,75810,84439,46928,950
Service and contract revenue3,1923,1618,9379,867
Total revenue18,95014,00548,40638,817
Cost of revenue:
Product cost of revenue7,5945,29019,16715,338
Service and contract cost of revenue1,3391,3603,9974,210
Total cost of revenue8,9336,65023,16419,548
Gross profit10,0177,35525,24219,269
Operating expenses:
Research and development3,8193,83710,88812,071
Selling, general and administrative11,9809,13433,00729,712
Change in fair value of contingent consideration-30510,70812,51819,999
Total operating expenses15,49423,67956,41361,782
Loss from operations-5,477-16,324-31,171-42,513
Other income, net8481,4432,6394,958
Loss from continuing operations before income taxes-4,629-14,881-28,532-37,555
Income tax benefit (expense), net50-29104-100
Net loss from continuing operations-4,579-14,910-28,428-37,655
Net income (loss) from discontinued operations, net of tax-7252,970
Net income (loss) attributable to common stockholders-4,579-14,982-28,42815,315
Net income (loss) from continuing operations per share attributable to common stockholders, basic and diluted-0.11-0.41-0.74-1.05
Net income (loss) from discontinued operations per share attributable to common stockholders, basic and diluted$—$—$—1.48
Net income (loss) per share attributable to common stockholders, basic and diluted-0.11-0.41-0.740.43
Weighted average common shares outstanding
Basic and diluted41,069,05336,101,05138,554,02735,791,111

Income Statement

Three Months Ended — Reconciliation from Gross Profit (GAAP) to Adjusted Gross Profit (Non-GAAP) and Margin Percentage:

Three Months Ended – September 30, – 2026Three Months Ended – September 30, – 2025Nine Months Ended – September 30, – 2026Nine Months Ended – September 30, – 2025
Gross Profit (GAAP)10,0177,35525,24219,269
Intangible amortization7856352,1541,904
Acquisition and integration costs50
Restructuring99288
Stock-based compensation136158397381
Adjusted Gross Profit (Non-GAAP)10,9478,14827,80221,892
Gross Margin Percentage (GAAP)53.0%53.0%52.0%50.0%
Adjusted Gross Margin Percentage (Non-GAAP)58.0%58.0%57.0%56.0%

Balance Sheet

September 30, — (unaudited)

September 30, – 2026December 31, – 2025
Current assets:
Cash, cash equivalents and marketable securities99,122112,970
Accounts receivable, net17,21911,327
Inventory14,69312,990
Prepaid expenses and other current assets4,1117,272
Total current assets135,145144,559
Operating lease, right-of-use assets4,7294,397
Property and equipment, net4,4404,232
Goodwill10,244
Intangible, net44,06636,412
Other long-term assets734471
Total assets199,358190,071
Current liabilities:
Accounts payable and accrued expenses11,0058,424
Deferred revenue11,5928,934
Operating lease liabilities and other liabilities2,29016,706
Total current liabilities24,88734,064
Deferred revenue, net of current portion11,2918,331
Contingent consideration, net of current portion8,189
Other long-term liabilities5,1883,977
Total liabilities49,55546,372
Total stockholders' equity149,803143,699
Total liabilities and stockholders' equity199,358190,071

Cash Flow

From the 10-Q · Nine Months Ended September 30, — The following table summarizes our sources and uses of cash for each of the periods presented: (in thousands)

Nine Months Ended September 30, – 2026Nine Months Ended September 30, – 2025
Cash provided by (used in) operating activities1,565-25,007
Cash provided by (used in) investing activities-6,36143,937
Cash used in financing activities-691-283
Effect of foreign exchange rate changes on cash and cash equivalents-10327
Net increase (decrease) in cash, cash equivalents and restricted cash-5,59018,674

This press release includes “forward looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts are forward-looking statements, including, without limitation, statements regarding the Company’s future revenue and growth and future business prospects and market opportunities. Words such as “may,”

“will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on management’s current expectations and involve known and unknown risks, uncertainties and assumptions which may cause actual results to differ materially from any results expressed or implied by any forward-looking statement, including the risks outlined under “Risk Factors” and elsewhere in the Company’s filings with the Securities and Exchange Commission (SEC) which are available on the SEC's website at www.sec.gov. Additional information will be made available in our annual and quarterly reports and other filings that we make from time to time with the SEC. Although the Company believes that the expectations reflected in its forward-looking statements are reasonable, it cannot guarantee future results. The Company has no obligation, and does not undertake any obligation, to update or revise any forward-looking statement made in this press release to reflect changes since the date of this press release, except as may be required by law.

​

Contact:

Matt Roache

VP, Investor Relations mroache@908devices.com

​

​

​

908 DEVICES INC.

Condensed Consolidated Statements of Operations

(in thousands, except share and per share amounts)

(unaudited)

​

​

​

​

​

​

908 DEVICES INC.

Condensed Consolidated Balance Sheets

(in thousands)

(unaudited)

​

​

​

​

​

​

908 DEVICES INC.

Reconciliations of GAAP to Non-GAAP Financial Measures

(Unaudited, amounts in thousands, except percentage and per share data)

In all tables below, totals may not add due to rounding

​

​

​

Reconciliation from Gross Profit (GAAP) to Adjusted Gross Profit (Non-GAAP) and Margin Percentage:

​

​

​

​

Reconciliation from Net Income (Loss) from Continuing Operations (GAAP) to Adjusted EBITDA (Non-GAAP):

​

​

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · 908 Devices earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.